SRPT up 75% because the FDA is letting them contin

SRPT up 75% because the FDA is letting them continue with their muscular dystrophy drug -- with a "confirmatory clinical trial." How big a market can that be, since it is a rare disease? Imagine what the percentage would be had it been something like, for instance, psoriasis, or cancer, or a new antibiotic.....

http://www.fiercebiotech.com/biotech/sarpeta-...0ifQ%3D%3D